PDCD1 and non-small cell lung carcinoma: Their overexpression has been described in various solid tumors with marked clinical therapeutic effects due to the checkpoint blockade [anti-PD1/PD-L1 antibodies] [2], revolutionizing the treatment of solid malignancies, particularly metastatic melanoma, renal cell carcinoma, and non-small cell lung carcinoma (NSCLC).